Skip to Main Content

A leading association of eye doctors has warned its members about safety concerns about Novartis’ new eye drug, sending the company’s stock down sharply Monday while that of Regeneron Pharmaceuticals, which produces a competing product, rose.

The American Society of Retina Specialists sent its membership an email about the drug, Beovu, on Sunday, warning that some doctors were reporting not just a known side effect, eye inflammation, but also a new one, vasculitis. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • “Murray argued that it was important that health plans not dictate which drug patients try first for cost reasons.”- I wish he would have been asked why. Is it because he would not want to be dictated to use this drug with a safety signal, or because he he just thinks it is important that physicians can write any medication regardless of cost? Or, if he has evidence-based reasons to support why it is important.

Comments are closed.